aTyr Pharma to Participate in April Investor Conferences
aTyr Pharma Announces Fourth Quarter and Full Year 2023 Results
aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2023 Financial Results
Tyr Pharma Announces Expanded Access Program (EAP) for EFZO-FIT¢ Clinical Trial Participants
aTyr to Present Posters Highlighting Importance of Neuropilin-2
aTyr Pharma Announces Howard University President Emeritus Dr. Wayne A. I. Frederick as Advisor for efzofitimod program in interstitial lung disease (ILD).
SAN DIEGO, Nov. 13, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its...
Phase 3 EFZO-FIT„¢ study of efzofitimod in pulmonary sarcoidosis expected to complete enrollment early in the second quarter of 2024. Phase 2 EFZO-CONNECT„¢ study of efzofitimod in SSc-ILD initiated...
aTyr Pharma announces that it will present at two investor conferences in November 2023.
aTyr Pharma Announces Dosing of First Patient in Phase 2 Study of Efzofitimod